Introduction
Anumana is a Cambridge, Massachusetts digital health company founded in 2021 that develops FDA-cleared artificial intelligence algorithms analyzing standard 12-lead electrocardiograms to detect cardiovascular conditions often missed by visual interpretation alone. The company was co-founded by nference and Mayo Clinic; Murali Aravamudan serves as executive chairman of the board and Maulik Nanavaty as chief executive officer per Anumana’s about page.
On April 8, 2026, Anumana announced FDA clearance of its ECG-AI algorithm for cardiac amyloidosis — described as the first and only cleared device for that indication using standard 12-lead ECGs. The software analyzes ECG waveforms to detect patterns associated with amyloidosis that human readers frequently overlook, integrating into existing workflows without requiring additional testing at the point of care.
Anumana’s portfolio strategy treats each new clearance as additive value on the same ECG acquisition — low ejection fraction, pulmonary hypertension, and amyloidosis detection from one routine test — a commercial model hospital cardiology service lines evaluate against standalone screening programs with separate billing and workflow overhead.
What the company does
Anumana builds software-as-a-medical-device algorithms that ingest ECG data already captured during routine care and return risk scores or suspicion flags clinicians use to prioritize confirmatory testing. Cleared products include ECG-AI for low ejection fraction, pulmonary hypertension (cleared March 28, 2026 per Anumana news), and cardiac amyloidosis (cleared April 8, 2026). Additional algorithms remain in development per company disclosures.
The cardiac amyloidosis algorithm was initially developed at Mayo Clinic and validated in a multi-center study of 25,525 patients across four U.S. health systems cited in the April 2026 release — reported sensitivity 78.9% and specificity 91.2% in adults presenting with signs, symptoms, or comorbidities of cardiac amyloidosis.
Who it serves
Anumana serves cardiologists, primary care networks, and health systems performing high ECG volumes where early heart failure, pulmonary hypertension, and amyloidosis detection can change referral timing. The about page emphasizes commercial deployment with established CPT codes and reimbursement pathways for cleared algorithms — a buying criterion for hospital CFOs beyond clinical sensitivity alone.
CEO Maulik Nanavaty is quoted in the April 2026 release on expanding a portfolio where each clearance adds detectable conditions from a single ECG — a platform narrative similar to multi-indication radiology AI but applied to cardiology’s most common screening test.
Company background
Anumana launched in 2021 as a joint venture leveraging nference’s AI infrastructure and Mayo Clinic cardiovascular expertise. Aravamudan — nference co-founder — serves as executive chairman; Nanavaty leads day-to-day operations as CEO with decades of medical device commercial experience per leadership bios. The company name derives from Sanskrit anumana, meaning inference — reflecting observation-and-reason approach to ECG interpretation.
Anumana’s about page cites modeling on nearly 2.9 million ECG-echo pairs and more than 30 peer-reviewed publications — evidence packages hospital AI committees request alongside FDA labels.
Product and AI capabilities
Anumana’s models apply deep learning to ECG voltage signals, extracting features invisible to standard visual reads. The cardiac amyloidosis clearance followed FDA Breakthrough Device Designation and participation in FDA’s Total Product Life Cycle Advisory Program pilot — regulatory pathways indicating higher-risk conditions where analytical validation scrutiny intensifies.
Because ECGs occur thousands of times daily in U.S. care settings, each new cleared indication increases marginal value of the same test without additional patient burden — Anumana’s commercial thesis health systems evaluate against standalone echo or biomarker screening programs.
Study co-principal investigators Martha Grogan, MD, and Angela Dispenzieri, MD, are quoted in the April 2026 release on validation across ATTR and AL amyloidosis subtypes at major referral centers — specificity matters because false-positive ECG-AI flags could cascade into unnecessary confirmatory testing if deployed without clinical protocols.
Key developments
2021: Anumana founded in Cambridge by nference and Mayo Clinic. Prior clearances: ECG-AI low ejection fraction and pulmonary hypertension (March 28, 2026). April 8, 2026: FDA clears ECG-AI cardiac amyloidosis algorithm with multi-center validation data cited in press release. January 12, 2026: Kevin Ballinger and Jean-Luc Butel joined board per Anumana news index.
Why it matters
Anumana matters because cardiac amyloidosis is frequently underdiagnosed while symptoms overlap common heart conditions — ECG-AI embedded in existing workflows could shorten time to confirmatory testing if hospitals implement results responsibly with human oversight. Anumana’s sequential FDA clearances test whether payers accept multi-algorithm ECG platforms as reimbursable screening infrastructure. Compare with consumer ECG leader AliveCor in portable ECG form factors and imaging AI in cardiology such as HeartFlow.
Early amyloidosis intervention can meaningfully alter outcomes per clinical literature cited in Anumana’s April 2026 release — the public-health argument for ECG screening depends on confirmatory testing pathways hospitals already operate, not AI flags alone.
Sector context
Anumana belongs in Brel’s AI in healthcare coverage under cardiovascular AI and SaMD, related to AliveCor personal ECG AI and precision medicine platforms such as Tempus AI operating on different multimodal datasets. Neurology EEG vendors like Beacon Biosignals share wearable biosignal AI methods applied to brain rather than cardiac electrical activity.
Sources and references
Anumana cardiac amyloidosis FDA clearance press release (April 8, 2026) and about page with leadership.
- Anumana — ECG-AI cardiac amyloidosis clearance (anumana.ai, April 8, 2026)
- Anumana — About Us (anumana.ai)
Reviewed July 10, 2026. Murali Aravamudan is executive chairman; Maulik Nanavaty is CEO. Founded 2021 in Cambridge.